NCT02452346View on ClinicalTrials.gov

Study of Clinical Efficacy and Safety of Tosedostat in MDS

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 20, 2015

Primary Completion Date

October 25, 2017

Study Completion Date

October 25, 2017

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Tosedostat

120 mg PO once daily continuously for each 28 day treatment cycle

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CTI BioPharma

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER